Sphera Funds Management Ltd. holds 1,993,496 Tenax Therapeutics common shares, representing a 5.33% ownership stake. The position matters to investors because the reporting parties state that the securities were not acquired or held to change or influence Tenax’s control, defining the disclosed interest as passive.

Key Highlights

  • Tenax’s reported ownership percentage is based on 37,423,917 common shares outstanding as of July 28, 2026.
  • The filing reports 174,375 shares held by Sphera Global Healthcare Master Fund and 1,819,121 shares held by Sphera Biotech Master Fund, L.P.
  • Adi Hanetz signed the ownership statements for three Sphera entities on August 27, 2026.

Sphera Funds Management Ltd. holds 1,993,496 shares of Tenax Therapeutics, Inc. (NASDAQ: TENX), representing 5.33% of its common stock. The position is reported on a passive basis, with the reporting parties certifying that the securities were not acquired or held to change or influence Tenax’s control.

Tenax Ownership Percentage Uses 37,423,917 Shares

The securities are common stock with a Par Value of $0.0001 per share. Sphera Global Healthcare Master Fund directly holds 174,375 shares, equal to 0.47% of the outstanding common stock, while Sphera Biotech Master Fund, L.P. directly holds 1,819,121 shares, equal to 4.86%.

Passive Filing’s Control Statement

The reporting parties state that the securities were not acquired or held for changing or influencing Tenax’s control. They also say the position is not connected with a transaction intended to produce that effect, apart from activities solely related to a nomination under the cited rule.

Peers Moving on This News